BB1 - BlinkLab Limited

[System]

BlinkLab Limited was incorporated on 17 August 2021 for the purpose of accelerating the development and commercialisation of intellectual property developed at Princeton University relating to smartphone-neurobehavioral testing (Licenced IP).

BlinkLab has the exclusive worldwide licence to commercialise the Licenced IP and has developed a smartphone-based application with an e-platform that serves as a medical device to perform neurometric tests to aid in the diagnosis of autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), schizophrenia and other neurodevelopmental conditions (BlinkLab Device). The tests include, but are not limited to, eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI) and habituation of eye blink response which serve as biomarkers for neurological and psychiatric disorders (BlinkLab Tests). The results from the BlinkLab Tests are recorded by smartphone and uploaded to BlinkLab’s confidential and secure online platform where the data is analysed using machine learning (ML).

Upon admission, the primary focus of BlinkLab will be to complete the necessary regulatory clinical studies and obtain the necessary regulatory approvals (that being FDA approval in the US and CE Mark in Europe) to bring the BlinkLab Device to market initially as a diagnostic tool for ASD.

It is anticipated that BB1 will list on the ASX during April 2024.

 

[Dona Ferentes]

Listing date	04 April 2024 #
Company contact	http://www.blinklab.org/ Ph: 02 9068 1925
Principal Activities	The development and commercialisation of a smartphone-based application with an e-Platform that serves as a medical device to perform neurometric tests to aid in the diagnosis of Autism, ADHD, Schizophrenia and other neurodevelopment and neuropsychiatric disorders.
Issue Price	AUD0.20
Issue Type	Ordinary Fully Paid Shares
Security code	BB1
Capital to be Raised	$7,000,000
Expected offer close date	21 March 2024
Underwriter	Not underwritten. Westar Capital Limited (Lead Manager)

 

[Dona Ferentes]

I can

Diagnosing autism and ADHD from a smartphone - ShareCafe

BlinkLab Limited (ASX:BB1) Non-Executive Chairman Brian Leedman discusses transforming smartphones into diagnostic tools.

www.sharecafe.com.au

 

[Dona Ferentes]

blink 1 time and you'd miss it?

19 November 2024
Large-Scale Study Validates and Enhances BlinkLab’s Accuracy in Detecting Autism in Children
Highlights
● Analysis of a study conducted in 441 children diagnosed for autism using current standard-of-care protocols showed that ‘BlinkLab Dx 1’ detected autism with an improved sensitivity of 91% and specificity of 85%.
● These results bolster confidence that BlinkLab Dx 1 will surpass the accuracy parameters required for regulatory approval in the upcoming FDA registration trial, scheduled to commence by the end of this calendar year.

Dec ...And doing something with FDA, regarding the regulatory pathway for BlinkLab Dx 1 diagnostic app.

Directors adjusting escrowed holdings